Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors.
In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic.
Read more at www.adcendo.com
Company Details
- Employees
- 66
- Founded
- -
- Address
- Nordre Fasanvej 215, Frederiksberg,capital Region Of Denmark 2000,denmark
- in****@****endo.dk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- adcendo.dk
- HQ
- Frederiksberg, Capital Region of Denmark
Adcendo Questions
Adcendo's website is adcendo.dk
Adcendo's LinkedIn profile is https://dk.linkedin.com/company/adcendo
Adcendo has
66 employees.
View email and phone details for 66
employees at Adcendo.
Adcendo's industry is
Biotechnology Research
Adcendo's top competitors are
Muna Therapeutics,
Zealand Pharma,
Minervax Aps,
Evaxion A/s,
Hemab Therapeutics,
Io Biotech,
Immudex,
Genmab,
Acesion Pharma,
Ascendis Pharma.
Adcendo's support email address is info@adcendo.dk
Adcendo's categories are Biotechnology Research
Adcendo's founding year is 2017
